Department of Neurology, University Hospital, Ludwig Maximilians Universität, Munich, Germany.
Department of Pediatric Neurology, Developmental Medicine, Social Pediatrics, Dr. von Hauner Children's Hospital, LMU - University Hospital, Ludwig Maximilians Universität, Munich, Germany.
Mol Genet Genomic Med. 2022 Dec;10(12):e2051. doi: 10.1002/mgg3.2051. Epub 2022 Sep 7.
Mutations in SOX6 have recently been recognized as a new molecular cause of neurodevelopmental disorders characterized by intellectual disability, behavioral changes, and nonspecific facial and digital skeletal abnormalities. To date, <25 cases have been reported in the literature.
Here we report a new case of SOX6-associated neurodegeneration and expand the phenotype to include ceratoconus. The clinical picture consisted of early onset mildly reduced intellectual function, facial asymmetry, and dystonic tremor of hands and neck, substantially improved by levodopa. Skeletal abnormalities included scoliosis and hypertrophy of the mandibular coronoid process. A heterozygous de novo loss-of-function variant in SOX6 (c.277 C>T. p.Arg93*) was molecularly confirmed which leads to truncation of the SOX6 protein in its N-terminus, upstream of any known functional domain.
SOX6-associated neurodevelopmental delayis ultrarare with less than 25 cases described in the literature. We report a new case who presented with early-onset mildly reduced intellectual function, facial asymmetry, skeletal abnormalities and dystonic tremor of hands and neck, substantially improved by levodopa. Given the therapeutic implications, SOX6 mutations should be considered in patients with complex dystonia parkinsonism.
SOX6 基因突变最近被认为是一种新的神经发育障碍的分子病因,其特征为智力障碍、行为改变以及非特异性面部和数字骨骼异常。迄今为止,文献中仅报道了<25 例病例。
在这里,我们报告了一例新的 SOX6 相关性神经退行性疾病病例,并将表型扩展到包括圆锥角膜。临床表现为智力障碍早期轻度发病、面部不对称和手部及颈部的张力障碍性震颤,左旋多巴治疗显著改善。骨骼异常包括脊柱侧凸和下颌冠状突肥大。分子学证实 SOX6 中存在杂合性新生无功能变异(c.277C>T,p.Arg93*),导致 SOX6 蛋白在其 N 端截断,在任何已知功能域的上游。
SOX6 相关性神经发育延迟非常罕见,文献中仅描述了<25 例病例。我们报告了一例新病例,其表现为智力障碍早期轻度发病、面部不对称、骨骼异常和手部及颈部的张力障碍性震颤,左旋多巴治疗显著改善。鉴于治疗意义,在伴有复杂肌张力障碍性帕金森病的患者中应考虑 SOX6 突变。